Mefloquine one. Plasma concentrations of the (–)-enantiomer are significantly higher than those for the (+)-enantiomer, and the pharmacokinetics between the two enantiomers are significantly different. The (+)-enantiomer has a shorter half-life than the (–)-enantiomer. According to some research, the (+)-enantiomer is more effective in treating malaria, and the (–)-enantiomer specifically binds to adenosine receptors in the central nervous system, which may explain some of its psychotropic effects. Mefloquine was formulated at Walter Reed Army Institute of Research (WRAIR) in the 1970s shortly after the end of the Vietnam war. Mefloquine was number 142,490 of a total of 250,000 antimalarial compounds screened
International Association for the Treatment of Sexual Offenders (every single person's treatment and care is going to be different to what best fits that specific person). Every sex offender is different which is why their care and limits need to be properly customized for that individual in order to protect the people of the community and also to successfully prevent them from reoffending. The management of risk is an important part of treatment, but if there is only a limited focus on risk then it can lead to excessively confrontational therapeutic encounters, no close relationship between the offenders and clinicians (this can potentially make treatment unsuccessful because there